$LH

Vaughn Bryan T sold $67K of LH

Vaughn Bryan T (EVP and President, Diagnostics) sold 234 shares of LABCORP HOLDINGS INC. (LH) at $286.19 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vaughn Bryan T
Published Jul 6, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The disclosed sale is pre-arranged under Rule 10b5-1, which generally reduces the likelihood that the transaction reflects new negative information.

02

Market read

Traders may treat this as routine insider activity with limited fundamental impact, mainly relevant for sentiment/positioning.

03

What to watch

The sale size is modest and the plan is pre-arranged; without additional context (e.g., multiple concurrent filings), the signal-to-noise is low.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-06 after-hours/market close window (per timestamp), reflecting a 2026-07-02 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Labcorp Holdings (LH) by an EVP and President, Diagnostics.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH EVP and President of Diagnostics Vaughn Bryan T sold 234 shares at $286.19 on 2026-07-02 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment/flow optics.

Evidence & confidence

The filing is a small-to-moderate single-tranche sale with explicit 10b5-1 pre-arrangement, reducing interpretive value versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation or liquidity needs, so traders may still watch for follow-on sales.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Vaughn Bryan T

    EVP and President, Diagnostics; sold 234 shares at $286.19 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMedAI 9/10

Labcorp’s (NYSE:LH) Q3 2026 sales beat estimates

Labcorp reported Q3 2026 revenue of $3.81B, exceeding estimates by 1.2% and growing 6.9% YoY. Adjusted EPS was $4.78, a 2.9% beat. The company raised full-year revenue and EPS guidance. Operating margin remained steady at 10.6%, while free cash flow margin improved to 10.8%. Organic revenue grew 5.5% YoY.

$LHHighAI 8/10

Labcorp shares edge up on beating estimates, raising guidance

Labcorp Holdings Inc. (NYSE:LH) reported Q3 earnings of $4.78 per share, beating estimates by $0.13, with revenue of $3.81 billion, up 6.9% YoY. The company raised full-year guidance for revenue growth to 5.9%-6.7% and adjusted EPS to $18.30-$18.70. Shares rose 1.46% in pre-market trading. Labcorp also announced four acquisitions and paid $58.2 million in dividends.

$LHHighAI 9/10

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

LABCORP HOLDINGS INC. (LH) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Contact: Nickolo Russo - Investors Racquel White - Media Investor@labcorp.com Media@labcorp.com Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance • Results from operations for third quarter 2026 versus third quarter 2025: ◦ Re